Market Overview

UPDATE: Jefferies Raises PT on Abbott Laboratories on Attractive Valuation

Related ABT
Time To Buy Mylan's Clear Path To EPS Upside, JP Morgan Says
Goldman Is Downgrading Abbott Laboratories

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $40.00 to $42.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Abbott Laboratories closed on Tuesday at $36.55.

Latest Ratings for ABT

Nov 2015Goldman SachsDowngradesBuyNeutral
Oct 2015BarclaysUpgradesEqual-weightOverweight
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters